Brief: Hyloris Announces FDA Approval Of Maxigesic IV
18/10/2023 06:10
Oct 18 (Reuters) - Hyloris Pharmaceuticals SA HYL.BR :
* HYLORIS ANNOUNCES U.S. FDA APPROVAL OF MAXIGESIC® IV
* FIRST U.S. SALES EXPECTED IN EARLY 2024, TRIGGERING A
MILESTONE
PAYMENT OF USD 2,1 MILLION
Source text for Eikon: ID:nGNE85D4QH
Further company coverage: HYL.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hyloris Pharmaceuticals SA
See all newsEurope Research Roundup: Akzo Nobel, MTU Aero Engines, Symrise
Brief: Hyloris Pharmaceuticals Says It Obtains Exclusive License Rights In Europe & Turkey From Arbormed For Its Wilson's Disease Therapy
Brief: Hyloris Announces Partnership With Rosemont Pharmaceuticals For Atomoxetine Oral Solution In The U.S.
Brief: Hyloris Announces Positive Study Results For Dofetilide IV
Brief: Hyloris Pharmaceuticals SA Says HY 2024 Revenues (Royalties And Milestones) Increased To EUR 4,2 Million